US manufacturing hits 4-year high, with AI buildout a major driver of growth, though price volatility looms: survey


Manufacturing activity in July hit a four-year high, with massive AI infrastructure investment a major driver of growth — even as industry leaders sounded the alarm over price volatility, according to a survey released Monday.

The Institute for Supply Management’s July manufacturing gauge jumped to 55.6 – expanding at its fastest pace since May 2022 and marking its seventh consecutive month of growth, the survey said.

President Trump has called for a return to US manufacturing. REUTERS

Any reading above 50 in the ISM’s monthly survey indicates growth while any measure below 50 signals contraction.

Susan Spence, chair of the ISM Manufacturing Business Survey Committee, said increased certainty around President Trump’s tariff policy and hopes for a more permanent deal to end the war in Iran helped encourage the boost in manufacturing.

“My gut is, it’s not just a one- or two-month trend,” Spence told reporters. “Companies are seeing six or more months of these solid demand factors going in the right direction.”

The survey’s gauge for production jumped to 58.5, its highest level since the end of 2021; the employment measure hit 52.8, rising for the first time in nearly three years; and new orders growth, which signals demand, also increased.

Massive business investments in AI infrastructure helped drive the expansion, along with political pressure to ramp up US manufacturing, according to experts.

Despite the growth in manufacturing, individuals’ responses to the ISM survey were overwhelmingly negative, with many industry leaders calling out price shocks from the Iran war and the chances that the Fed could raise interest rates next month to counter inflation fears.

“Pricing volatility was mentioned in 57% of negative comments, the Iran war 43%, increasing lead times 22% and tariffs 18%,” Spence said.

Among the survey responses, one metals producer remarked that “it makes me yearn for the coronavirus pandemic chaos, which was more manageable than whatever this is that we are in.”

The Institute for Supply Management’s July manufacturing gauge jumped to 55.6. AFP via Getty Images

Some transportation equipment manufacturers lamented increased costs and transit time “for rerouted shipments due to conflicts in the Red Sea, Strait of Hormuz and Suez Canal.”

Others noted that a spike in demand for certain electronics supplies due to the AI race was “challenging on-time fulfillment for our supply chains.”

Jackson Barnes, CEO of Novo, a financial platform for small businesses, said the build-out of massive AI data centers is largely driving manufacturing investments – but that has a lopsided impact on the industry. 

“Look at where the demand is coming from. It’s coming from semiconductors, AI infrastructure and defense. Those are capital-intensive supply chains dominated by large manufacturers,” Barnes told The Post.

Massive business investments in AI infrastructure helped drive the expansion, according to experts. Getty Images

“That gap shows up clearly in what we see. Across the small manufacturers we work with, the median firm’s quarterly revenue is down roughly 12% from two years ago, even though total volume across that same group is up about 14%.”

Tech giants like Meta and Microsoft have announced planned capital expenditures this year of as much as $145 billion and $190 billion, respectively, as they ramp up their AI efforts.

Rising oil prices amid the Iran war have multiplied costs for nearly every manufacturer – and the concern for many in the industry is that the Federal Reserve could soon raise interest rates as a result, which could hit their growth streak.

Overall, it was a strong report, according to experts, as all but one manufacturing industry reported growth in July — including electrical equipment, appliances and components and computer and electronic products. Chemical products marked the only sector that contracted over the month.

“I would say that a lot of the tech investment right now has a lag,” said Amrita Bhasin, co-founder and CEO of Sotira and a manufacturing expert. “There is a lot of money being poured into AI infrastructure and that infrastructure is very resource-intensive.”

“I am optimistic just because we’ve got a lot of factors that are all coinciding at the right time,” Bhasin told The Post.

Free Training

Source link

Factbox-Global drugmakers rush to boost US presence as tariff threat looms | WKZO | Everything Kalamazoo


March 9 (Reuters) – Global drugmakers are ramping up U.S. manufacturing and stockpiling inventory as the Trump administration considers a 100% tariff on imported branded and patented medicines.

Although enforcement is delayed for companies investing in U.S. manufacturing, the policy has already prompted fast-tracked projects, price cuts and direct-to-consumer sales.

Pfizer and AstraZeneca secured multi-year tariff exemptions through pricing deals and commitments to the new TrumpRx.gov platform. Eli Lilly, Johnson & Johnson and Merck have pledged billions to expand U.S. operations to avoid penalties.

Here’s what drugmakers are doing to mitigate supply-chain risks and reassure investors:

Pfizer

Pfizer reached a deal with President Donald ​Trump on September 30 to invest $70 billion in research and development and domestic manufacturing, and received a three-year grace period exempting its products from the pharmaceutical-targeted tariffs.

GSK

The London-based drugmaker plans to invest $30 billion in ‌U.S. research and development and supply chain infrastructure over five years.

Eli Lilly

U.S. President Donald Trump said in January that Eli Lilly plans to build six plants in the United States.

Lilly said last year that it planned to spend at least $27 billion to build four U.S. plants to expand production and bolster medical supply chains. The company has since announced details on three plants, in Alabama, Virginia and Texas.

Lilly in January said it will build a $3.5 billion pharmaceutical manufacturing facility in Pennsylvania, its fourth new site, in an effort to expand U.S. production and bolster medical supply chains.

Johnson & Johnson

The drugmaker plans to raise U.S. investments by 25%, totaling $55 billion, over the next four years. It plans to build four plants, including one at Wilson, North Carolina, and another at Tokyo-based Fujifilm Biotechnologies’ manufacturing site in Holly Springs, North ‌Carolina, over ​the next 10 years.

The company said in February it would invest more than $1 billion to build a new cell therapy facility in Pennsylvania, part of ⁠its larger plans announced last year to scale up U.S. manufacturing.

Roche

The ⁠Swiss drugmaker said in April last year it would invest $50 billion in the U.S. over the next five years.

A month later, it announced an additional $550 million investment to expand its Indianapolis diagnostics manufacturing hub. The expansion will span Indiana, Pennsylvania, Massachusetts, and California, creating more than 12,000 jobs.

In January, Roche said it will more than double its investment in its drug manufacturing facility in Holly Springs, North Carolina, to about $2 billion, up from the over $700 million announced in May 2025.

AstraZeneca

The Anglo-Swedish drugmaker will invest $50 billion on U.S. manufacturing by 2030. The investment will fund a new drug substance facility in Virginia, its largest single-site global investment, alongside expansions ​in Maryland, Massachusetts, California, Indiana and Texas.

It has already started technology transfers and is managing inventory in 2025 to minimize any tariff hit. Company executives have said the impact would be “very short-lived.”

Novartis

The Swiss drugmaker plans to spend $23 billion to build and expand 10 facilities in the U.S. over the next five years. This includes building six new manufacturing plants and expanding its San Diego research and development site, which is expected to create more than 1,000 ⁠jobs.

Sanofi

The French drugmaker plans to invest at least $20 billion in the U.S. through 2030 to boost manufacturing and research. Sanofi plans to ⁠expand its U.S. manufacturing capacity through direct investments in the company’s sites and partnerships with other domestic manufacturers.

Chief Financial Officer François Roger said in July the potential tariffs are ​expected to have a limited impact in 2025, as the company already has inventory in place in the U.S.

Biogen

The U.S. drugmaker will invest $2 billion more in its existing manufacturing plants in North Carolina, adding capacity for gene-targeting therapies and automation. The ​company has seven factories in the state, with an eighth set to begin operations in late 2025.

Merck

The U.S. drugmaker has begun building a $3 billion pharmaceutical manufacturing plant in Virginia ‌as part of its over $70 billion investment to expand domestic manufacturing and research and development.

It will also invest $1 billion in a new Delaware plant to make biologics and cancer drug Keytruda, to boost U.S. production and potentially create over 4,500 jobs. It also opened a $1 billion facility at its North Carolina site in March.

Merck’s animal health unit will invest $895 million to expand its Kansas manufacturing and R&D site, part of a broader $9 billion U.S. investment through 2028.

CEO Robert Davis in July flagged minimal impact from potential tariffs in 2025, and that the company remained well-positioned due to inventory management and moving of manufacturing to the U.S.

Amgen

The U.S.-based biopharma firm plans to invest $900 million to expand its Ohio manufacturing facility, bringing total ⁠investment in the state to $1.4 billion and adding 750 jobs. In December, the company committed $1 billion to build a second facility in Holly Springs, North Carolina.

Amgen said in September it is investing more than $600 million to build a new research and development center at its headquarters in Thousand Oaks, California.

The drugmaker announced it will invest $650 million to expand drug manufacturing at its facility in Juncos, Puerto Rico, a move expected to create nearly 750 jobs.

Novo Nordisk

The Danish ⁠pharmaceutical company said in August its strong U.S. manufacturing footprint positions it well for ‌tariff challenges, describing itself as “very U.S.-centric and U.S.-focused”.

AbbVie

U.S. drugmaker AbbVie said in January it has committed $100 billion over the next decade to U.S.-based research and development as ⁠part of its three-year deal with the Trump administration to reduce drug prices.

It has 11 manufacturing sites in the U.S. and has said it is “fairly insulated” from ​any tariff impact this ‌year, given inventory management actions.

The company said in February that it plans to invest $380 million to build two manufacturing facilities at its current North Chicago, ​Illinois, campus, to support the ⁠production of its neuroscience and obesity medications.

Gilead Sciences

Earlier this year, the drugmaker announced $11 billion in new planned investment in the U.S. to add to its domestic manufacturing and research heft, taking its total pledged investment to $32 billion.

Gilead said in September that it started work on a pharmaceutical development and manufacturing hub at its headquarters in Foster City, California, in addition to which, it is currently developing two other sites.

Cipla

The Indian drugmaker is expanding its U.S. manufacturing footprint by investing in capacity expansion for complex respiratory products at its advanced facilities in Fall River, Massachusetts, and Central Islip, New York.

CSL

Australia’s CSL said in November it would invest $1.5 billion in the U.S. to manufacture plasma-derived therapies, expanding its footprint in the country over the next five years.

In March, the company announced the expansion of its plasma therapy manufacturing facility in Kankakee, Illinois, which is expected to be operational by 2031.

(Reporting by Siddhi Mahatole, Kamal Choudhury, Puyaan Singh, Sneha S K and Sahil Pandey in Bengaluru; Editing ​by Tasim Zahid, Sahal Muhammed, Shinjini Ganguli and Maju Samuel)

Free Training

Source link